Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Management of common types of arthritis in older adults 

Management of common types of arthritis in older adults
Chapter:
Management of common types of arthritis in older adults
Author(s):

James B. Galloway

and David L. Scott

DOI:
10.1093/med/9780198701590.003.0075
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 10 July 2020

The main forms of inflammatory arthritis are rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. They are long-term disorders and consequently their prevalence increases with age; the lifetime risk of developing rheumatoid arthritis is over 3% in women. Their characteristic features comprise joint pain, swelling, and tenderness, morning stiffness, and general symptoms such as malaise. Polyarthritis is commoner in rheumatoid arthritis. The ESR and C-reactive protein levels are high in active arthritis. The main radiological finding is erosive disease. Symptomatic treatment includes analgesics and non-steroidal anti-inflammatory drugs. Disease-modifying drugs (DMARDs) change the course of these diseases; their main use is in rheumatoid arthritis. Biologic drugs help when other treatments are insufficient; they include tumour necrosis factor inhibitors which benefit all types of inflammatory arthritis, and other biologics targeting B- and T-cells are mainly used in rheumatoid arthritis. The risks of adverse events and drug toxicity are higher in elderly patients.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.